Caldera Therapeutics and Vidya Therapeutics Announce Mergers Amid Biotech Industry Consolidation
Biotechnology startups Caldera Therapeutics and Vidya Therapeutics have announced mergers with established but struggling biotechs, adding to a recent wave of industry consolidation. Caldera, founded in late 2025 with $112.5 million in venture capital, is merging with Synlogic while securing an additional $278 million through private financing for its drug candidate CLD-423, which targets inflammatory diseases like ulcerative colitis and Crohn's disease. Vidya Therapeutics has also announced a merger with Processa Pharmaceuticals to advance its Bruton’s tyrosine kinase inhibitor (BTKi) VT-7208. The compound is in late-stage development for conditions including food allergies, chronic urticaria, and multiple sclerosis. Vidya secured $200 million from over 10 firms alongside the deal. Both mergers aim to extend financial runway into 2029 while navigating a challenging biotech funding environment marked by limited IPO opportunities.
Topics: biotechnology IPO market slump mergers and acquisitions